Immix Biopharma, Inc. Senior Director / Executive Director, Site Activation & Patient Services Remote · Full time Company website

Apply for Senior Director / Executive Director, Site Activation & Patient Services

We are seeking a strategic, hands-on commercial leader to build the capabilities that ensure every eligible patient can access NXC-201 quickly, reliably, and seamlessly.

At Immix, we are developing NXC-201, a differentiated BCMA-directed CAR-T therapy with Breakthrough Therapy designation with lead indication in relapsed/refractory AL amyloidosis. As we advance toward anticipated US launch in 2027, we are building the commercial capabilities required to bring this transformative therapy to patients with significant unmet need.

This is a rare opportunity to build one of the most critical capabilities for a successful CAR-T launch. The Senior Director / Executive Director, Site Activation & Patient Services will define the strategy, partnerships and operating model that enable treatment centers to confidently adopt NXC-201 while delivering an exceptional provider and patient experience.

Initial success will be measured by developing and executing a scalable strategy for activating Authorized Treatment Centers (ATCs) in advance of launch. Longer term, this role will help shape the evolution of our treatment center network, patient services capabilities and operating model as commercial experience grows and customer needs evolve.

What You Will Do

Enable Treatment Centers to Deliver NXC-201

• Develop and execute the strategy for activating US ATCs
• Design the site activation operating model, playbooks, readiness criteria, success metrics and continuous improvement processes
• Partner with Sales Leadership to develop the field engagement model and drive consistent execution across the commercial organization
• Partner closely with Medical Affairs to coordinate treatment center engagement while maintaining appropriate functional roles
• Collaborate directly with Legal to prepare agreements, coordinate review of contract redlines, negotiate business terms and facilitate timely execution
• Lead cross-functional efforts to identify and remove barriers to treatment center readiness while continuously improving the activation experience

Create an Exceptional Provider & Patient Experience

• Define the strategy for provider services, patient support, and treatment center experience
• Lead the strategic relationship with patient support program (PSP) hub partner
• Help shape the end-to-end treatment journey to ensure operational processes integrate seamlessly into treatment center workflows
• Serve as the voice of treatment centers, providers, patients and caregivers across cross-functional planning and decision-making
• Continuously improve the provider and patient experience through operational excellence, customer insights and strong external partnerships

Lead Strategic Partnerships

• Lead the strategic relationship with Specialty Distribution / 3PL partner and other critical external cell orchestration service providers
• Help define the operating model, governance and performance expectations for strategic partners supporting commercialization
• Partner across Commercial, Medical Affairs, Commercial Operations, Quality, Technical Operations, Manufacturing, Regulatory Affairs, and external partners to ensure a coordinated, reliable treatment journey
• Influence cross-functional decisions that improve operational execution while maintaining unwavering focus on ATC, provider, patient and caregiver needs

Drive Launch Readiness

• Serve as the business owner for site activation strategy and ATC readiness
• Develop the capabilities, tools and metrics required to support a successful launch
• Identify operational risks early and lead cross-functional mitigation planning
• Help shape the long-term strategy for expanding treatment center network and supporting commercial growth following launch.

Qualifications

Education & Experience

• Bachelor's degree required; advanced degree (MBA, PharmD or equivalent) preferred
• 10+ years of progressive experience within the biopharmaceutical industry
• Direct, hands-on experience leading or supporting site activation for an autologous CAR-T launch required
• Experience supporting commercial launch of cell therapies in hematology/oncology strongly preferred
• Experience working directly with ATCs
• Demonstrated success leading complex cross-functional initiatives and managing strategic external partners
• Experience in emerging biotechnology or launch-stage organizations preferred

Capabilities

• Deep understanding of autologous CAR-T treatment workflows and treatment center operations
• Demonstrated ability to translate strategy into execution in fast-paced, resource-constrained environments
• Proven ability to influence cross-functional teams
• Strong customer orientation with a deep appreciation for provider, patient, and caregiver experience
• Excellent communication, relationship-building, and problem-solving skills
• High degree of ownership, initiative, accountability, and intellectual curiosity

Distinctive Strengths

·        Equally comfortable developing strategy and engaging directly with treatment centers to solve complex operational challenges

·        Able to build trusted relationships with physicians, treatment centers and external partners through credibility, responsiveness, and execution

• Collaborative, low-ego leader who can work across functions to achieve shared goals

·        Thrives in ambiguity and enjoys building new capabilities from the ground up

·        Motivated by the opportunity to help bring a potentially transformative therapy to patients with significant unmet need

Location & Travel

• US-based, remote
• Ability to travel up to 25% as required

About Immix Biopharma

Immix Biopharma is committed to harnessing the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting.

Our lead asset, NXC-201, is a differentiated BCMA-directed CAR-T therapy being developed for relapsed/refractory AL amyloidosis—an area of critical unmet need. We are advancing rapidly toward potential approval and launch, with the goal of bringing a transformative therapy to patients.

We are guided by three core values: Intelligence, Integrity, and Initiative. We are building a team of thoughtful, driven individuals who are motivated by the opportunity to make a meaningful impact for patients and to help define the future of our company.